Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication ... Dec 22
The broad-spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being developed by ImmuneMed, is on track to progress as a treatment for the ... Dec 21
Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment. The trial did not meet key end-points ... Oct 21
Vir Biotechnology, Inc. and GlaxoSmithKline today announced the global expansion to Phase 3 of the COMET-ICE study for the early treatment of COVID-19 ... Oct 06
-Advertisements-